Follicular lymphoma is an indolent malignancy with a generally favorable prognosis, with survival often measured in decades.

A 2012 study of patients with low-tumor-burden follicular lymphoma showed that the 4-year freedom from treatment failure rate ...

As a lymphoma survivor, I struggle with the positivity trap — sometimes, I just want my fears validated instead of being ...

Follicular lymphoma is a diverse disease, both biologically and clinically. Patients may present with indolent, asymptomatic disease or more aggressive, symptomatic disease with high tumor burden.

Life after treatment for follicular lymphoma brings long-term physical and emotional challenges, including immune system impacts and lasting social effects.

Visit us on Facebook. Opens in a new tab or window Visit us on X. Opens in a new tab or window Visit us on Instagram. Opens in a new tab or window Visit us on LinkedIn. Opens in a new tab or ...

These forward-looking statements reflect HUTCHMED's current expectations regarding future events, including its expectations regarding the therapeutic potential of tazemetostat for the treatment of ...

China’s National Medical Products Administration (NMPA) has granted conditional approval for Hutchmed’s Tazverik ...

Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences' rival Yescarta.

Following a successful Type B end-of-phase 2 meeting, the FDA has approved the start of a phase 3 trial of linperlisib in peripheral T-cell lymphoma.

TAZVERIK ® is a registered trademark of Epizyme Inc., an Ipsen company.

Get Instant Summarized Text (Gist) Advancements in circulating tumor DNA (ctDNA) detection offer significant potential for improving lymphoma management. ctDNA analysis, a noninvasive alternative ...